Intratumoral CAN2109 in Subjects With Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorCanwell Biotech Limited
About this trial
A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.
Eligibility criteria
Qualifiers
Able and willing to provide written informed consent and willing to comply with the study's requirements.
Male or female age ≥ 18 years at screening.
Performance status of 0-1 on the ECOG Performance Scale.
Disqualifiers
Unresolved toxicities from prior therapy, defined as having not resolved to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (v5.0) Grade 0 or 1, with exception of endocrinopathies from prior therapy, alopecia, and vitiligo.
Treatment with systemic corticosteroids at doses exceeding 10 mg/day prednisone or equivalent.
Has an active infection requiring systemic therapy.
New York Heart Association Class 3 or 4 congestive heart failure
Trial design
Treatments tested in this trial
- CAN2109
Treatment groups
27 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov